Moderna Inc (MRNA)
Quick ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 1,927,000 | 1,644,000 | 2,478,000 | 2,051,000 | 2,907,000 | 2,932,000 | 3,801,000 | 3,441,000 | 3,205,000 | 3,027,000 | 2,873,000 | 5,048,000 | 6,848,000 | 5,550,000 | 5,603,000 | 5,442,000 | 2,624,000 | 1,505,580 | 1,761,630 | 391,720 |
| Short-term investments | US$ in thousands | 5,098,000 | 5,223,000 | 6,010,000 | 6,472,000 | 5,697,000 | 4,641,000 | 4,658,000 | 5,482,000 | 6,697,000 | 5,321,000 | 5,024,000 | 5,067,000 | 3,879,000 | 3,356,000 | 2,387,000 | 2,293,000 | 1,984,000 | 1,770,720 | 955,384 | 825,981 |
| Receivables | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 2,206,000 | 2,201,000 | 2,363,000 | 2,380,000 | 3,015,000 | 4,385,000 | 3,123,000 | 3,499,000 | 4,923,000 | 6,807,000 | 6,812,000 | 9,238,000 | 9,128,000 | 9,957,000 | 8,840,000 | 8,441,000 | 4,389,000 | 1,473,560 | 161,647 | 134,582 |
| Quick ratio | 3.18 | 3.12 | 3.59 | 3.58 | 2.85 | 1.73 | 2.71 | 2.55 | 2.01 | 1.23 | 1.16 | 1.09 | 1.18 | 0.89 | 0.90 | 0.92 | 1.05 | 2.22 | 16.81 | 9.05 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($1,927,000K
+ $5,098,000K
+ $—K)
÷ $2,206,000K
= 3.18
The quick ratio of Moderna Inc has shown significant fluctuations over the last few years. It started at a high level of 9.05 on March 31, 2020, indicating a strong ability to cover its short-term liabilities with its most liquid assets. However, the ratio decreased sharply to 0.90 by June 30, 2021, which may have raised concerns about the company's short-term liquidity position.
The ratio remained below 1 for several quarters, indicating a potential challenge in meeting short-term obligations with its quick assets alone. However, there was a notable improvement in the quick ratio from December 31, 2021, to March 31, 2022, suggesting a strengthened liquidity position.
Subsequently, the quick ratio continued to increase, reaching 3.59 as of June 30, 2024, signaling a significant improvement in the company's ability to meet short-term obligations comfortably. This upward trend indicates that Moderna Inc has enhanced its liquidity position over the years, which could lead to improved financial stability and reduced liquidity risk in the future.
Peer comparison
Dec 31, 2024